CMC Technical Writer (Contract)
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.
Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work® in 2026.
Description of Role
The CMC Technical Writer role will critically review data, methods, batch records, and various development, campaign, and production reports from external CDMOs to finalize source documents for analytical, drug substance and drug product. The CMC Technical Writer should also then be able to write scientific and regulatory content and author and prepare report summaries and conclusions from the source documents for final document repository.
&